pSivida Corp. (PSDV)

2.22
0.06 2.42
NASDAQ : Health Technology
Prev Close 2.27
Open 2.26
Day Low/High 2.13 / 2.27
52 Wk Low/High 0.93 / 2.88
Volume 300.85K
Avg Volume 358.80K
Exchange NASDAQ
Shares Outstanding 45.16M
Market Cap 51.94M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
PSivida And Pfizer Amend Agreement To Focus Solely On Development Of Sustained-Release Implant To Deliver Latanoprost For Ocular Hypertension And Glaucoma

PSivida And Pfizer Amend Agreement To Focus Solely On Development Of Sustained-Release Implant To Deliver Latanoprost For Ocular Hypertension And Glaucoma

Drug delivery company pSivida Corp (NASDAQ:PSDV)(ASX:PVA) today announced it amended and restated its Research and Development Agreement with Pfizer Inc.

PSivida Announces Resubmission Of New Drug Application For ILUVIEN®

PSivida Announces Resubmission Of New Drug Application For ILUVIEN®

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Sciences, Inc.

PSivida Corp. Reports Results For The Third Quarter Ended March 31, 2011

PSivida Corp. Reports Results For The Third Quarter Ended March 31, 2011

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the product candidate ILUVIEN® for the treatment of ...

PSivida Corp. Announces Third Quarter 2011 Financial Results Release Date And Conference Call Information

PSivida Corp. Announces Third Quarter 2011 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the third quarter of...

PSivida Announces New Safety And Efficacy Data From Phase 3 Study Of ILUVIEN® In Diabetic Macular Edema

PSivida Announces New Safety And Efficacy Data From Phase 3 Study Of ILUVIEN® In Diabetic Macular Edema

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the presentation of new data from the completed...

PSivida Corp. Reports Results For The Second Quarter Ended December 31, 2010

PSivida Corp. Reports Results For The Second Quarter Ended December 31, 2010

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the product candidate ILUVIEN® for the treatment of ...

PSivida Announces Positive Results From The 36 Month Readout Of Completed Phase 3 FAME™ Study Of ILUVIEN® In Patients With Diabetic Macular Edema

PSivida Announces Positive Results From The 36 Month Readout Of Completed Phase 3 FAME™ Study Of ILUVIEN® In Patients With Diabetic Macular Edema

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of...

PSivida Corp. Announces Second Quarter 2011 Financial Results Release Date And Conference Call Information

PSivida Corp. Announces Second Quarter 2011 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN(R) for the treatment of...

PSivida Completes Previously Announced Registered Direct Financing

PSivida Completes Previously Announced Registered Direct Financing

pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of...

PSivida Announces $10.75 Million Registered Direct Financing

PSivida Announces $10.75 Million Registered Direct Financing

pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of...

FDA Issues Complete Response Letter Regarding New Drug Application For ILUVIEN®

FDA Issues Complete Response Letter Regarding New Drug Application For ILUVIEN®

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of...

PSivida Corp. To Present At The Maxim Group Growth Conference

PSivida Corp. To Present At The Maxim Group Growth Conference

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the product candidate Iluvien® for the treatment of...

PSivida Corp. Reports Results For The First Quarter Ended September 30, 2010

PSivida Corp. Reports Results For The First Quarter Ended September 30, 2010

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the product candidate Iluvien® for the treatment of...

PSivida Corp Awarded Two Therapeutic Discovery Project Grants Totaling $489,000

pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in the development of sustained release drug delivery products for the treatment of back-of-the-eye disease including the product candidate Iluvien™ for the ...

PSivida Corp Announces First Quarter 2011 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in the development of sustained release drug delivery products for the treatment of back-of-the-eye disease including the product candidate Iluvien™ for the ...

PSivida Ranked 15th On 2010 Technology Fast 500™, Deloitte’s Ranking Of Fastest Growing Companies In North America

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for the treatment of back of the eye disease including the product candidate Iluvien™ for the ...

pSivida - Upgrades & Downgrades

TheStreet Ratings released rating changes on 12 U.S. common stocks for September 23, 2010. Seven stocks were downgraded and five stocks have been upgraded by our stock model.

PSivida Corp. Reports Fourth Quarter And Fiscal Year 2010 Financial Results

PSivida Corp. Reports Fourth Quarter And Fiscal Year 2010 Financial Results

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back of the eye diseases, including the product candidate Iluvien™ for the treatment of ...

PSivida Corp Announces Fourth Quarter And Fiscal Year 2010 Financial Results Release Date And Conference Call Information

PSivida Corp Announces Fourth Quarter And Fiscal Year 2010 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leader in the development of sustained release drug delivery systems for difficult-to-treat, back-of-the-eye conditions, today announced that its financial results for...

PSivida To Webcast Presentation At Rodman & Renshaw Health Care Conference

pSivida Corp, (NASDAQ:PSDV)(ASX:PSD), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that it will webcast a live presentation...

PSivida Announces Iluvien® Receives FDA Priority Review For Treatment Of Diabetic Macular Edema

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences...

PSivida Added To Russell Microcap Index

PSivida Added To Russell Microcap Index

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, announced that it has been added to the Russell...

PSivida Announces Submission Of Marketing Authorization Application For An Ophthalmic Product For Diabetic Macular Edema In Certain European Union Countries

PSivida Announces Submission Of Marketing Authorization Application For An Ophthalmic Product For Diabetic Macular Edema In Certain European Union Countries

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences...

PSivida Announces Submission Of NDA To FDA For An Ophthalmic Product For Diabetic Macular Edema

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences...

PSivida CEO To Speak At Glaucoma & Retinopathies 2010 Conference In London

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its president and CEO, Dr.

PSivida Corp. Reports Third Quarter Fiscal Year 2010 Financial Results

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA)(FF: PV3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back-of-the-eye diseases, today...

PSivida Corp Announces Third Quarter 2010 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leader in the development of back of the eye drug delivery systems, today announced that its financial results for the third quarter of fiscal year 2010 will be released...

Results Of Studies Using PSivida Technologies In Glaucoma And Degenerative Eye Diseases To Be Presented At Upcoming ARVO Meeting

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of back of the eye drug delivery systems, today announced that two poster presentations will be made at the upcoming ARVO meeting on one of ...

PSivida Receives $15 Million Payment From Alimera Sciences

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of ophthalmic sustained release drug delivery products, today said it had received full payment of a $15 million note, including an additional $225,000...

Newly-Published Peer-Reviewed Paper Shows Durasert Device Was Neuroprotectant In Retinitis Pigmentosa Model

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of ophthalmic sustained release drug delivery products, today said that a recently-published peer reviewed scientific paper showed that a sustained...